Cadila Healthcare Q3 PAT grows 68% as US biz jumps 78% on flu drug sales

Total income up 38% to Rs 33 bn; company launched two products, got 24 USFDA approvals in quarter

Ahmedabad-based Cadila Healthcare has posted a 68 per cent year-on-year (YoY) jump in net profit for the third quarter of the current fiscal on the back of a 78 per cent jump in its US business riding on Tamiflu and generic Lialda volumes.

The company reported a 38 per cent YoY increase in total income from operations to Rs 32.6 billion while the net profit had soared 68 per cent to Rs 5.43 billion in Q3FY18. The  Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs 8.41 billion was up by 108 per cent on a YoY basis the